FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates SAB Biotherapeutics Announces Q1 2024 Financial Results

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...

SAB Biotherapeutics Provides SAB-142 Trial Update SAB Biotherapeutics provides update on SAB-142 clinical trial for type 1 diabetes

SAB Biotherapeutics to Present at INNODIA Annual Meeting SAB Biotherapeutics, Inc. today announced their Chief Medical Officer will share an overview of the SAB-142 clinical development plan at INNODIA.